IRB #

STUDY00020959

Title

A Phase 1, Dose Escalation Study of Intravenous TK216 in
Patients with Relapsed or Refractory Ewing Sarcoma - Expansion Cohort Segment Only

Principal Investigator

Lara Davis

Study Purpose

This study is being done to test the good and bad effects of TK216 in patients aged 10-100 years with relapsed or refractory Ewing sarcoma (ES) (includes patients with Ewing sarcoma family of tumors-ESFT).

Medical Condition(s)

Ewing sarcoma (ES), Ewing sarcoma family of tumors-ESFT

Eligibility Criteria

1. Patients, both male and female, aged 10 years or older
2. Have confirmed diagnosis of Ewing sarcoma (ES), including patients with Ewing sarcoma family of tumors-ESFT
3. Adequate organ function
4. Other criteria apply

Age Range

10 - 100

Healthy Volunteers Needed

No

Duration of Participation

24 months

Minors Included

Yes

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Oncternal Therapeutics, Inc.

Recruitment End

01/31/2022

Compensation Provided

No


Go Back